thymus extract is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The Pakistan–United States trade deal was concluded with a bilateral deal in Washington D.C. after intensive negotiations in July 2025, involving Pakistan's Finance Minister Muhammad Aurangzeb and Foreign Minister Ishaq Dar, alongside U.S. Trade Representative Jamieson Greer and Commerce Secretary Howard Lutnick. On 30–31 July 2025, President Donald Trump publicly confirmed the agreement via social media, calling it a "historic" energy partnership. Prime Minister Shehbaz Sharif hailed it as a "landmark deal" enhancing their enduring partnership.
== Assays for DBH activity in human serum and cerebrospinal fluid == DBH activity in human serum could be estimated by a spectrophotometric method or with the aid of ultra-high-performance liquid chromatography with photo diode array detector (UHPLC-PDA). A sensitive assay for the detection of DBH activity in cerebrospinal fluid using high-performance liquid chromatography with electrochemical detector (HPLC-ECD) was also described earlier.
chloroplast DNA (cpDNA, chDNA, ctDNA) The set of DNA molecules contained within chloroplasts, a type of photosynthetic plastid organelle located within the cells of some eukaryotes such as plants and algae, representing a semi-autonomous genome separate from that within the cell's nucleus. Like other types of plastid DNA, cpDNA usually exists in the form of small circular plasmids.
Ehrenfreund et al. (2001) found that amino acids in CI chondrites Ivuna and Orgueil were present at much lower concentrations than in CM chondrites (~30%), and that they had a distinct composition high in β-alanine, glycine, γ-ABA, and β-ABA but low in α-aminoisobutyric acid (AIB) and isovaline. This implies that they had formed by a different synthetic pathway, and on a different parent body from the CM chondrites.
=== Propaganda === Cyber propaganda is an effort to control information in whatever form it takes, and influence public opinion. It is a form of psychological warfare, except it uses social media, fake news websites and other digital means. In 2018, Sir Nicholas Carter, Chief of the General Staff of the British Army stated that this kind of attack from actors such as Russia "is a form of system warfare that seeks to de-legitimize the political and social system on which our military strength is based". Jowell and O'Donnell (2006) state that "propaganda is the deliberate, systematic attempt to shape perceptions, manipulate cognitions, and direct behavior to achieve a response that furthers the desired intent of the propagandist" (p. 7). The internet is the most important means of communication today. People can convey their messages quickly across to a huge audience, and this can open a window for evil. Terrorist organizations can exploit this and may use this medium to brainwash people. It has been suggested that restricted media coverage of terrorist attacks would in turn decrease the number of terrorist attacks that occur afterwards.
Sources: en.wikipedia.org
American biochemist, botanist, plant geneticist, and drosophilist W. Wallace Cleland (1930–2013). American biochemist at the University of Wisconsin–Madison known for work on enzyme kinetics and mechanism. Member Natl. Acad. Sci. USA. G. Marius Clore FRS (b. 1955). British-American biochemist at the NIH known for work in protein and nucleic acid structure determination by nuclear magnetic resonance spectroscopy. Member Natl. Acad. Sci. USA.
Treatment of intraarticular fracture usually falls into conservative (nonsurgical) or surgical management depending on the degree of displacement or movement of the fractured piece from native alignment. Treatment often relies on fracture reduction with use of sedation or local anesthetic to attempt to reset the alignment into tolerances that favor bone healing. This is often done in an emergency room setting or clinic and the patient may be placed into an immobilization device such as a splint or cast to allow time for healing. Surgical intervention is most common in cases of intraarticular fractures because it allows direct visualization of the joint surface to help mediate chances of posttraumatic osteoarthritis. Risks of surgical intervention include blood loss, infection, and problems with wound healing. Most commonly, open reduction internal fixation (ORIF) is the modality used which utilizes plates and screws to restore alignment of the fracture. Recently, there has been a push for minimally invasive options, such as percutaneous pinning, secondary to wound complications with use of ORIF. With pinning, intraoperative radiography is used to drive screws through the skin. However, with this technique, there continues to be some risk of posttraumatic arthritis due to the joint surface not being viewed during operation. Even with perfect joint alignment there continues to be a risk of posttraumatic arthritis.
"Current map of sea surface temperature anomalies in the Pacific Ocean". earth.nullschool.net. "Southern Oscillation diagnostic discussion". Climate Prediction Center. National Oceanic and Atmospheric Administration. "ENSO Outlook – An alert system for the El Niño–Southern Oscillation". Australian Bureau of Meteorology. Provides current phase of ENSO according to the Australian interpretation. "Cold & Warm Episodes by Season / Relative Oceanic Niño Index (RONI): Historical El Niño / La Niña episodes (1950–Present)". National Oceanic and Atmospheric Administration (NOAA).
In the red giant stars of the asymptotic giant branch, the s-process (slow process) is ongoing to produce bismuth-209 and polonium-210 by neutron capture as the heaviest elements to be formed, and the latter quickly decays. All elements heavier than it are formed in the r-process, or rapid process, which occurs during the first fifteen minutes of supernovae. Bismuth-209 is also created during the r-process.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.